Our Methodology

Here is a description of the criteria we use to select biotech companies.

Science for Life - this is what we support.

BiotechProfSchleuning focuses on companies in the healthcare and biotechnology sector. Our spectrum ranges from companies with newly developed molecules to therapuetic platform technologies and novel medical devices.

We focus on companies that have one or more drugs/preparations/applications in clinical phase 3. For our companies, we strive for direct, personal contact with (a) scientific management and (b) CEOs.

We pursue companies that convince us mainly by the scientific approach and a top-class scientific team. Thus, one or the other Nobel Prize winner can be found in the companies.

Our methodology - unique and scientific.

Our team scans 1,500 biotech companies according to pre-defined, scientific core criteria. About 15 to 30 companies remain in the mesh. We subject these companies to a deeper review: again the scientific data and additionally an initial economic review. About 3 to 8 companies remain.

We establish direct contact with these remaining companies. The companies are subjected to a deep, intensive science analysis by our team as well as by other external specialists. Statistical/mathematical methods are used to calculate different scenarios for the probability of success of the products.

An insight - four examples

Company Protein

Proprietary protein therapeutics with clinically improved profiles – that is what this company is engaged in. The therapeutic protein candidate is in Phase III clinical trials for the treatment of Fabry disease.

The company is focused on recombinant therapeutic proteins produced by a proprietary protein expression system based on plant cells. Potentially clinically superior versions of recombinant therapeutic proteins targeting established pharmaceutical markets are currently under development. These include a proprietary recombinant form of human deoxyribonuclease I from plant cells for the treatment of cystic fibrosis and a recombinant PEGylated uricase expressed in plant cells for the treatment of gout. Company Protein can develop and commercialize recombinant proteins without infringing on the method-based patents or other intellectual property rights of third parties. The system used has lower scale-up (CapEx) and production costs, and can develop therapeutic proteins for clinical trials faster than other platforms. Thus Company Protein has a unique technology platform and in-house research and development capabilities.

Company protein has already received FDA approval for one product, another is in Phase III clinical trials, and other products are in Phase IIa.

Company Cell Therapy

Company Cell Therapy focuses on the development and commercialization of bone marrow transplant (BMT) therapies and other adaptive cell therapies. Its lead candidate product is in a pivotal Phase III clinical trial for elderly people with relapsed or refractory acute myeloid leukemia for BMT conditioning.

The Company Cell Therapy develops focused radiation therapies based on its own technology platform. The company is currently researching a clinical-stage, multi-disease, multi-target pipeline of antibody-radiation conjugates that can be used for targeted conditioning and as therapeutic agents. The conjugates can potentially be used either in combination with other therapeutic modalities (in collaboration with other companies) or as a single agent for patients with hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. The conjugates offer highly effective and selective forms of radiation therapy that enable precise targeting of their proven therapeutic power to tumors and synergistic potential with other therapeutic modalities that cannot be achieved with conventional external beam radiation, cytotoxic chemotherapy or biological therapies. Through its technology platform, the company aims to use multiple radioisotopes to meet the specific requirements of the desired indication.

The company is a leader in using a potent alpha-emitting radioisotope and has demonstrated the ability to isotopically target both hematologic and solid tumors.

Company Plasma

The company’s lead product candidate is in Phase 3 clinical trials for the treatment of excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy.

This company’s new drug development approach is based on the use of a proprietary controlled release technology that improves the way drugs are dosed and released.

The current drug is a once-per-night extended-release formulation. The once-per-night drug may be safer due to consequences associated with the dosing regimen of the previously approved twice-per-night product.

Company Fusion Protein Therapeutics

Company Fusion Protein Therapeutics focuses on the development and commercialization of targeted fusion protein therapeutics (TFPTs) for the treatment of cancer patients.

The company’s lead product candidates include a locally administered targeted fusion protein that is in Phase III clinical trials for the treatment of Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) and a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors.

While BCG is effective in many patients, challenges with tolerability have been observed and many patients experience disease recurrence. When BCG is not effective or a patient can no longer receive BCG, the recommended treatment option is radical cystectomy, the complete removal of the bladder.

Criteria for analysis

More than 100 criteria are included in the algorithm we developed to evaluate the companies.


Here is a small excerpt.

The excerpt shown is again only an extract, behind which stand individual analyses by our science team as well as third scientists.


If you have any further questions, please feel free to contact us.